Company Overview and News
MONTREAL, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Champion Iron Limited (ASX: CIA, TSX: CIA)(“Champion” or the “Company”) advises that at an Annual General Meeting of the Company’s shareholders (the “Meeting”) which was held in Montreal, Quebec on August 17, 2018, the following resolutions were passed by the requisite majorities by a vote by way of show of hands and by ballot as follows:
CHPRF CIA CIA
MONTREAL, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Champion Iron Limited (TSX: CIA, ASX:CIA) reports that its wholly-owned subsidiary Champion Iron Mines Limited (the “Company” or “Champion”) is pleased to disclose results of recent exploration drilling at its Powderhorn property, located in North Central Newfoundland, 40 km southwest of the town of Springdale. This program intersected several zinc (“Zn”) rich intervals, including drill hole PH18-01 which intersected 3.
CHPRF CIA CIA
MONTRÉAL, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Champion Iron Limited (TSX: CIA) (ASX: CIA) (“Champion” or the “Company”) is pleased to announce the appointment of Ms. Natacha Garoute, LLB, CPA, CA, as the Company’s Chief Financial Officer.
CHPRF CIA CIA SEMFF
MONTRÉAL, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Champion Iron Limited (TSX:CIA) (ASX:CIA) (“Champion Iron” or “The Company”) is pleased to announce that, with the successful production ramp-up of its Bloom Lake Iron Ore Mine (“Bloom Lake”), it reported strong operational and financial results for the 2019 financial year first quarter ended June 30, 2018 (see Champion Iron’s filings on SEDAR dated August 7, 2018).
CHPRF CIA CIA
MONTRÉAL, March 27, 2018 (GLOBE NEWSWIRE) -- Quebec Iron Ore Inc. (“QIO”), a Champion Iron Limited (ASX:CIA) (TSX:CIA) (“Champion” or the “Company”) subsidiary, is pleased to announce that preparation for the first shipment of Bloom Lake Iron Ore Mine (“Bloom Lake”) high quality iron ore is underway following the arrival of the MV Magnus Oldendorff at the Port of Sept-Îles on March 25, 2018.
CHPRF CIA CIA
MONTRÉAL, 27 mars 2018 (GLOBE NEWSWIRE) -- Minerai de fer Québec Inc. (« MFQ »), une filiale de Champion Iron Limited (ASX: CIA)(TSX: CIA) (la «société» ou «Champion»), a confirmé aujourd’hui que le premier chargement de concentré de fer de haute qualité, en provenance de la mine de fer du Lac Bloom, a débuté le 25 mars 2018 à la suite de l’arrivée du MV Magnus Oldendorff au Port de Sept-Îles.
CHPRF CIA CIA
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:CIA / Champion Iron Limited on message board site Silicon Investor.